These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 54910)

  • 1. [Raveron treatment of prostatic adenoma in the light of uroflowmetry (on the basis of 20 cases)].
    Janosz F; Zieliński J
    Pol Przegl Chir; 1975 Nov; 47(11A):1441-4. PubMed ID: 54910
    [No Abstract]   [Full Text] [Related]  

  • 2. [Urine flowmetry in patients with prostatic adenoma treated with Raveron].
    Steinmetz L; Adamkiewicz K
    Pol Przegl Chir; 1974 Oct; 46(10A):1375-82. PubMed ID: 4139698
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of urination disorders with Raveron].
    Ichim V
    Z Urol Nephrol; 1970 Apr; 63(4):255-60. PubMed ID: 4109019
    [No Abstract]   [Full Text] [Related]  

  • 4. [Medical treatment of prostatic adenoma. Urinary flow data].
    Giglio V; Campo B; Motta M
    Minerva Urol; 1972; 24(3):104-7. PubMed ID: 4141047
    [No Abstract]   [Full Text] [Related]  

  • 5. [Double-blind test on the therapeutic effects of a prostatic extract in the clinical syndrome of prostatic adenoma].
    Arduini M; Trucchi E
    Minerva Urol; 1972; 24(5):167-72. PubMed ID: 4141050
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of raveron and levorin on urination recovery in prostatic adenoma and chronic prostatitis].
    Savin VF; Antonov NM; Arkannikov AB
    Urol Nefrol (Mosk); 1982; (2):22-4. PubMed ID: 6177084
    [No Abstract]   [Full Text] [Related]  

  • 7. [Electrophoretic studies of normal prostate homogenate and of adenoma, with special reference to the prostate homogenate of patients treated with Raveron].
    Fabris P; Mori G; Ingrami A
    Arch Ital Urol; 1966 Aug; 38(5):391-404. PubMed ID: 4169901
    [No Abstract]   [Full Text] [Related]  

  • 8. [An allergic reaction after raveron administration].
    Belova IV; Anokhina MA; Chamkin GV
    Urol Nefrol (Mosk); 1990; (2):70-1. PubMed ID: 1695038
    [No Abstract]   [Full Text] [Related]  

  • 9. Raveron versus placebo in the conservative treatment of benign prostatic hyperplasia (BPH).
    Bircan K; Ozen HA; Ergen A; Başar I; Ozgür S; Ilker Y; Karaağaoğlu E; Remzi D
    Int Urol Nephrol; 1990; 22(4):345-8. PubMed ID: 1699907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of the effect of prostate extracts].
    Costa J; Guedes JM; Reis MO
    J Med (Oporto); 1965 Dec; 58(196):1024-7. PubMed ID: 4159123
    [No Abstract]   [Full Text] [Related]  

  • 11. [On drug therapy of prostatic hypertrophy].
    Rieben W
    Praxis; 1967 Jul; 56(30):1042-7. PubMed ID: 4180980
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tumorous prostatic diseases. I. Prostatic adenoma--genesis, clinical aspects, therapy].
    Reichelt H
    Z Allgemeinmed; 1974 May; 50(15):688-93. PubMed ID: 4137484
    [No Abstract]   [Full Text] [Related]  

  • 13. [Raveron in the combined treatment of patients with chronic nonspecific prostatitis].
    Stekhun FI
    Vestn Dermatol Venerol; 1987; (9):58-62. PubMed ID: 3424988
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapeutic effect of Robaveron tablet (KN-7) on urinary disturbance by benign prostatic hypertrophy].
    Sonoda T; Endo H; Maru A; Sasaki K; Kuroda K; Takamura T; Inada F; Rokuzyo M; Ohori T; Kubo T
    Hinyokika Kiyo; 1985 Mar; 31(3):553-62. PubMed ID: 2411118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of Raveron in adenomectomies].
    Kanô H; Silva EC
    Z Urol Nephrol; 1978 Mar; 71(3):175-9. PubMed ID: 77603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Action of the combination of hypothalamic phospholipids and megestrol acetate (IP 11) in prostatic hypertrophy. Results of a controlled clinical trial].
    Mazza G; Petracco S
    Minerva Urol; 1974; 26(6):293-300. PubMed ID: 4142804
    [No Abstract]   [Full Text] [Related]  

  • 17. [Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
    Matsuura T; Wakabayashi A; Kaneko S; Kurita T
    Hinyokika Kiyo; 1986 Jun; 32(6):903-6. PubMed ID: 2429533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of prostamol-UNO in the treatment of patients with initial symptoms of prostatic adenoma and risk of progression: 2 years of investigations].
    Aliaev IuG; Apolikhin OI; Mazo EB; Vinarov AZ; Lokshin KL; Medvedev AA; Permiakova OV; Spivak LG; Shkol'nikov ME
    Urologiia; 2009; (4):36-40. PubMed ID: 19824382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tadenan in the treatment of prostatic adenoma. Anatomo-clinical study].
    Bongi G
    Minerva Urol; 1972; 24(4):129-39. PubMed ID: 4141048
    [No Abstract]   [Full Text] [Related]  

  • 20. [Medical treatment of prostatic adenoma].
    Schulman CC; Chantrie M; Giannakopoulos X; De Sloover CR
    Brux Med; 1979 Oct; 59(10):467-70. PubMed ID: 94841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.